Tag Archives: Patent Law

“Obamacare” Survives – Including Path to Generic Biologicals

Biotech patent attorneys rejoice – no matter if you represent generic companies or NDA holders,  the 5-4 decision of the Supreme Court upholding the “individual mandate” – not under the commerce clause, but as an appropriate use of Congress’ power to … Continue reading

Posted in Follow-On Biologics | Tagged , , , , , , , | Leave a comment

Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…

Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Will Universities Benefit from their Micro Entity Applicants?

In an introductory post on the USPTO’s proposed rules: “Changes to Implement Micro Entity Status for Paying Patent Fees,” 77 Fed. Reg. 31806 (May 30 2010), my partner, Gary Speier, spent some time on new 35 USC 123(a), which defines … Continue reading

Posted in AIA Patent Reform, Patent Reform Legislation | Tagged , , , , , | 1 Comment

Lather. Rinse. Repeat — In re Baxter International, Inc.

The following is a guest blog from Ron Schutz of Robins, Kaplan, Miller & Ciresi. It just got it easier for infringers to use reexamination as a way to wash a judicial patent validity determination right out of their hair. … Continue reading

Posted in Post-issuance procedures, Reexamination | Tagged , , , , , , , , , , | Leave a comment